About Geron Corporation
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Imetelstat exhibits relatively preferential inhibition of the clonal proliferation of malignant progenitor cells in nonclinical studies. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: GERN
- CUSIP: 37416310
- Previous Close: $2.15
- 50 Day Moving Average: $2.11
- 200 Day Moving Average: $2.21
- 52-Week Range: $1.81 - $3.35
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -26.88
- P/E Growth: -2.24
- Market Cap: $350.12M
- Outstanding Shares: 159,145,000
- Beta: 2.82
- Net Margins: -469.51%
- Return on Equity: -21.96%
- Return on Assets: -20.88%
Companies Related to Geron Corporation:
- Current Ratio: 15.74%
- Quick Ratio: 15.74%
What is Geron Corporation's stock symbol?
Geron Corporation trades on the NASDAQ under the ticker symbol "GERN."
Where is Geron Corporation's stock going? Where will Geron Corporation's stock price be in 2017?
3 brokers have issued 12-month target prices for Geron Corporation's stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Geron Corporation's share price to reach $5.00 in the next year.
When will Geron Corporation announce their earnings?
Geron Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns Geron Corporation stock?
Geron Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (14.90%), State Street Corp (2.87%), State Board of Administration of Florida Retirement System (0.09%), A.R.T. Advisors LLC (0.08%) and Metropolitan Life Insurance Co. NY (0.07%). Company insiders that own Geron Corporation stock include Olivia Kyusuk Bloom and Thomas Hofstaetter.
Who sold Geron Corporation stock? Who is selling Geron Corporation stock?
Geron Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC.
Who bought Geron Corporation stock? Who is buying Geron Corporation stock?
Geron Corporation's stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, A.R.T. Advisors LLC and Metropolitan Life Insurance Co. NY.
How do I buy Geron Corporation stock?
Shares of Geron Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Geron Corporation stock cost?
One share of Geron Corporation stock can currently be purchased for approximately $2.15.